Pixuvri

The marketing authorisation for Pixuvri (Pixantrone) expired on 12 June 2024 following the decision of the marketing authorisation holder, Les Laboratoires Servier, not to apply for a renewal of the marketing authorisation. Les Laboratoires Servier confirmed that it did not apply for renewal of the authorisation due to the lack of demand for this product. Pixuvri was granted marketing authorisation in the European Union (EU) on 10 May 2012 for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphomas. The marketing authorisation was a conditional marketing authorisation which was subsequently converted to a full marketing authorisation in 2019 and was valid for a 5-year period. Therapeutic alternatives are available throughout the European Union. The European Public Assessment Report (EPAR) for Pixuvri is updated to indicate that the marketing authorisation is no longer valid.